Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v3-EN
Language French English
Date Updated 2021-12-03 2021-11-25
Drug Identification Number 02435268 02435268
Brand name BIVALIRUDIN FOR INJECTION BIVALIRUDIN FOR INJECTION
Common or Proper name Bivalirudin for Injection 250 mg/vial SD Vial 10 mL Bivalirudin for Injection 250 mg/vial SD Vial 10 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients BIVALIRUDIN BIVALIRUDIN
Strength(s) 250MG 250MG
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 10 mL 10 mL
ATC code B01AE B01AE
ATC description ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2021-11-24 2021-11-24
Actual start date 2021-11-24
Estimated end date 2022-01-03 2022-01-03
Actual end date
Shortage status Actual shortage Actual shortage
Company comments Sandoz is an alternate supplier of Bivalirudin for Injection and have been informed of our impending supply interruption. Sandoz is an alternate supplier of Bivalirudin for Injection and have been informed of our impending supply interruption.
Health Canada comments